Curia Completes Upgrade of API Aseptic Suites in Valladolid, Spain

ALBANY, N.Y., May 19, 2026 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization, today announced the completion of its upgrade to its two aseptic suites in Valladolid, Spain. The $4 million dollar investment is in accordance with the EU’s GMP Annex 1 standards.
The central feature of the upgrade was the transition to a fully closed system, designed to strengthen process and product integrity while minimizing microbiological risk across all stages of production. Enhancements also focused on modernizing core equipment and systems, including the installation of advanced isolators, as well as upgrades to HVAC, pharmaceutical utilities, automation and sterilization-in-place processes.
“This investment at Valladolid reflects Curia’s commitment to delivering high-quality sterile manufacturing capabilities that align with the growth plans of our customers,” said Philip Macnabb, CEO of Curia. “These facility enhancements position us as a stronger partner when it comes to producing increasingly complex sterile products while maintaining the high standards of quality assurance that regulators and customers expect.”
By advancing its aseptic capabilities, Curia will be able to offer greater flexibility, reliability and speed. With advanced, fully closed processing and enhanced contamination control at its core, the Valladolid facility is positioned to deliver consistent, high-quality supply at scale—reinforcing Curia’s role as a partner of choice for critical sterile programs.
About Curia
Curia is a contract research, development and manufacturing organization (CDMO) with over 30 years of experience, an integrated network of 20+ global sites and 3,100 employees partnering with biopharmaceutical customers to bring life-changing therapies to market. Our offerings in small molecule, generic APIs and biologics span discovery through commercialization, with integrated regulatory, analytical and sterile fill-finish capabilities. Our scientific and process experts, along with our regulatory-compliant facilities, provide a best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate your research and improve patients’ lives. Visit us at curiaglobal.com.
| Corporate Contact: |
| Viana Bhagan |
| Curia |
| +1 518 512 2111 |
| corporatecommunications@CuriaGlobal.com |
标签:



热点文章
Ledger 中国销售渠道说明:广州馨潇贸易有限公司官方直营渠道公示
L'ATELIER DE JOËL ROBUCHON HONG KONG 延续十八载辉煌传奇 今夏载誉回归置地廣塲
从“眼巴巴”到“手飒飒”,5年59次打破国外技术垄断——国家管网集团北京管道有限公司“红色劲旅自主维保突击队”攻坚实录
2025年度全国会计专业技术中级资格考试 (甘肃考区)报名公告
品誉咨询——绩效破局:从 “效率优先” 到 “效能质变” 的管理范式革新
远程星智F3E正式上市!“小卡六边形战士”直击城配用户运营痛点
香港国际机场飞赏圣诞礼遇
世贸通移民集团:2025年十大移民事件